Daily Archives: December 4, 2017

NTS Ventures and IHMA Announce a Collaborative Agreement to Provide an Extensive Suite of Clinical Mycology, Antifungal and Microbiology Laboratory Services to Support Anti-infective Drug Development to the Biopharmaceutical Industry

SCHAUMBURG, Ill., Dec. 04, 2017 (GLOBE NEWSWIRE) — NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service central clinical microbiology laboratory have announced a non-exclusive collaborative agreement that will provide the pharmaceutical industry with an extensive suite of mycology and antifungal testing services and microbiology testing services, including specialties in antibacterial agents and biofilms. The suite of services includes pre-clinical in vitro and in vivo antifungal services, mechanism of action investigations, full antifungal clinical trial services and regulatory services as well as microbiology support for clinical and surveillance studies and specialty testing studies.

The development of new anti-infectives has increased rapidly over the past ten years. The need to support these important, life-saving products has increased as well. The agreement between NTS and IHMA will allow all pharmaceutical and biotech companies access to mycological, antifungal and microbiology clinical laboratory testing that is required to develop and support antifungal and antimicrobial drugs. Both NTS and IHMA employ highly qualified and experienced clinical microbiologists and scientists with expertise in anti-infectives. With this collaboration, IHMA and NTS will be able to offer an extensive suite of mycology and antifungal testing services in addition to its existing all-encompassing suite of antibacterial services.

“This collaborative partnership integrating the outstanding capabilities at both IHMA and NTS creates a single destination for antimicrobial drug development, creating an incredibly efficient and expedient resource for the biopharmaceutical industry,” said Dr. Mahmoud Ghannoum, Founder of NTS Ventures.

“IHMA is very excited about this new relationship with NTS Ventures. This opportunity gives both organizations the ability to better support the biopharmaceutical industry’s goals to develop new and more potent antifungal and antibacterial agents,” said Dr. Daniel Sahm, Chief Scientific Officer and VP of Global Microbiology Services at IHMA, Inc.

ABOUT NTS Ventures

NTS is based in Cleveland, OH and provides preclinical, clinical and translational services designed to bring antifungal, antibacterial and dermatology agents from discovery to market. NTS has the ability to support drug development in preclinical and clinical testing phases in order to satisfy FDA Investigational New Drug (IND) and New Drug Application (NDA) submissions. Over the past 25 years the NTS team has worked with a large range of entities including global Big Pharma, start up and growth stage biotech companies, full-spectrum CRO’s as well as academic institutions.

For more information, please visit https://www.ntsventures.com.

ABOUT IHMA

IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.

For more information, visit the IHMA website at: www.ihma.com

CONTACT INFORMATION
Contact
Igael Hamburg
847-303-5003
ihamburg@ihma.com

Lantronix Launches Advanced Wireless Embedded IoT Gateways

— Compact xPico® 200 Gateways Deliver Versatile Connectivity and Intelligent Networking —

IRVINE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — Lantronix, Inc. (NASDAQ:LTRX), a global provider of secure data access and management solutions for the industrial Internet of Things (IoT), today announced the launch of its xPico® 200 embedded IoT gateways. Measuring less than the size of a postage stamp, the compact xPico 200 embedded IoT gateways deliver robust Ethernet, Wi-Fi and Bluetooth connectivity, enterprise-grade security, and integrated manageability features that are ideal for industrial IoT applications.

A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/988d87cf-075e-4acf-90a1-27b42d595c46

“Today’s advanced IoT applications require more than just simple connectivity,” stated Shahram Mehraban, Lantronix vice president of marketing. “With the commercial launch of our xPico 200 product family, Lantronix is providing a robust compact solution that combines best-in-class wired and wireless connectivity, industrial grade design and intelligent networking that enables resource-constrained product development teams to reduce total cost of ownership and time to market for their industrial IoT solutions.”

“With its state-of-the-art fast roaming capabilities and integrated manageability, the xPico 200 embedded gateways deliver reliable functionality and performance that will enable us to efficiently develop very cost competitive connected products,” said Paul Blashewski, president of Prescient Wireless.

Combining the Lantronix intelligent networking communications engine with Cypress Semiconductor’s industry-leading wireless SoC, the xPico 200 gateways deliver best-in-class managed industrial Wi-Fi connectivity that enables industrial OEMs to simplify and accelerate development of their smart connected solutions. Currently, the xPico 200 gateways are being designed into industrial, medical, retail, smart building and transportation verticals.

“Lantronix has developed an industry-leading secure embedded solution that enables OEMs to utilize the Cypress CYW43907 802.11n Wi-Fi MCU to provide network reliability and flexibility to do more,” said Andrew Hunter, senior director of marketing at Cypress Semiconductor. “The xPico 200 series represents another milestone in our collaboration with Lantronix and addresses the growing need for industrial IoT solutions that deliver robust connectivity, processing capabilities and manageability.”

The xPico 200 product family features include:

  • Highly integrated industrial grade Wi-Fi and versatile connectivity
    ° 
    Seamlessly integrated Wi-Fi, Ethernet and Bluetooth (BT and BLE) connectivity – no need to write complex drivers
    ° Dual-band 802.11a/b/g/n Wi-Fi delivers higher performance and reliability, minimizing interference
    ° Industrial grade design supporting long life and reliable operation in extreme environments
    ° Lantronix concurrent Soft AP + Client that provides device support and access without disrupting machine field operations
  • Robust data access and management
    ° 
    Intelligent networking and automatic connection management
    ° Field-tested TruPort® Serial and TruPort® Socket enable out-of-the-box connectivity locally and over the Internet for hundreds of serial machine protocols
    ° Built-in network communications engine simplifies embedded application development
    ° Pre-integrated with Lantronix MACH10™ IoT platform, including MACH10 Global Device Manager
  • Built-in comprehensive device security services
    ° 
    Enterprise-grade TruPort® Security ensure security of both data-at-rest and data-in-motion
    ° Secure connectivity to WPA2-Enterprise Wi-Fi networks
    ° Secure boot and secure FOTA (firmware over the air) features allow only authorized software to run on the gateway

The xPico 240 is available through the worldwide network of authorized Lantronix distributors and resellers. xPico 250 evaluation kits will be available this month with product availability in early 2018. For more information about the xPico 200 product family, go to www.lantronix.com/xpico-200 or contact a local Lantronix sales office.

About Lantronix  
Lantronix, Inc. is a global provider of secure data access and management solutions for Internet of Things (IoT) assets. Our mission is to be the leading supplier of IoT solutions that enable companies to dramatically simplify the creation, deployment, and management of IoT projects while providing secure access to data for applications and people.

With more than two decades of experience in creating robust machine to machine (M2M) technologies, Lantronix is an innovator in enabling our customers to build new business models and realize the possibilities of the Internet of Things. Our connectivity solutions are deployed inside millions of machines serving a wide range of industries, including industrial, medical, security, transportation, retail, financial, environmental and government.

Lantronix is headquartered in Irvine, California. For more information, visit www.lantronix.com.

Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

Lantronix Media and Analyst Contact:  
E.E. Wang
Director, Corporate Marketing and Investor Relations
media@lantronix.com
investors@lantronix.com
949-614-5879

Lantronix Sales: 
sales@lantronix.com
Americas +1 (800) 422-7055 (US and Canada) or +1 949-453-3990
Europe, Middle East and Africa +31 (0)76 52 36 744
Asia Pacific + 852 3428-2338
China + 86 21-6237-8868
Japan +81 (0) 50-1354-6201
India +91 994-551-2488

© 2017 Lantronix, Inc. All rights reserved. Lantronix, TruPort and xPico are registered trademarks, and MACH10 is a trademark, of Lantronix Inc. Wi-Fi is a registered trademark of Wi-Fi Alliance. The Bluetooth word mark and Bluetooth Smart Ready are registered trademarks owned by the Bluetooth SIG, Inc. Other trademarks and trade names are those of their respective owners.

SpeeDx Pty. Ltd. establishes US-based operation

Subsidiary prepares for expected 2018 US product launch

SYDNEY, Australia, Dec. 04, 2017 (GLOBE NEWSWIRE) — SpeeDx Pty. Ltd, a developer of advanced multiplex molecular diagnostic solutions, announced the incorporation of a US-based subsidiary company, SpeeDx Inc.   The parent company, headquartered in Australia, will use the US base to support current clinical trial activity for ResistancePlus™ MG (not currently for sale in the US), in preparation for an expected 2018 launch. The SpeeDx ResistancePlus™ MG test detects the sexually transmitted bacteria Mycoplasma genitalium along with mutations that confer resistance to azithromycin, the front-line antibiotic treatment of choice.

ResistancePlus™ MG will potentially be a first-to-market molecular diagnostic test in the US, providing both detection of the MG infection along with information about antibiotic resistance of the disease.  The test previously received regulatory clearances in Europe, Australia and New Zealand and is already experiencing strong sales in those locations. SpeeDx recently signed a partnership agreement with Thermo-Fisher to help bring the ResistancePlus™ MG test to the US and a distribution agreement with Cepheid in Europe for their PlexPCR™ and ResistancePlus™ tests.

“We have always had the goal of bringing ResistancePlus MG to the US market”, said Colin Denver, CEO of SpeeDx, “local offices and staff will allow us to more easily navigate the FDA approval process and keep us on track for our product launch next year.”

A rapid rise in resistant strains of M. genitalium across the globe has led to international guidelines for the management of M. genitalium infections that recommend testing for macrolide resistance to better inform treatment options.1 With M. genitalium prevalence rapidly increasing in the US, and in some instances exceeding that of Chlamydia,2 it is expected that US guidelines will also be updated to address antimicrobial resistance in this significant sexually transmitted disease (STD).

“Our aim is to empower clinicians and physicians to make the best treatment decisions about the diseases they are faced with,” said Colin Denver.  “Ultimately, we want to support individualised patient management and better antimicrobial stewardship, which will help patients quickly receive the best treatment for their disease and for physicians to better address antibiotic resistance challenges.”

About MG
Mycoplasma genitalium can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than Gonorrhea.3 Like Gonorrhea, MG is also evolving into a so-called STI “superbug” that is becoming resistant to many antibiotic treatments, leading to exceedingly difficult-to-treat infections and threatening global public health.4

Macrolide antibiotics, specifically azithromycin, are the first-line treatment for M. genitalium infections, but resistance to these antibiotics has increased up to 50 percent in several countries.4  New European Guidelines for the treatment of M. genitalium infections were released last year recommending the molecular detection of M. genitalium with an assay capable of detecting macrolide resistance-associated mutations.1 Timely detection of antibiotic resistant infections enables better treatment of the disease, lessens the potential for spreading among vulnerable populations and combats the rising level of antibiotic resistance.

Currently, there is not a commercially available, FDA-cleared molecular diagnostic test for the detection of MG.

About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI M. genitalium (ResistancePlus™ MG) that combines detection of the disease with detection of markers for antibiotic resistance. For more information about SpeeDx please see: http://www.plexpcr.com

1 Jensen, JS. et al 2016. 2016 European Guidelines on Mycoplasma genitalium Infections.
2 Getman D et al. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a
multicenter clinical study cohort in the United States. J ClinMicrobiol 2016; 54:2278–2283.
3 Centers for Disease Control and Prevention, 2015 Sexually Transmitted Diseases Treatment Guidelines.
4 Unemo, M & Jensen, JS. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. 2016. Nat. Rev. Urol. 268. Published online 10 Jan 2017. doi:10.1038/nrurol

Contacts for SpeeDx:
Madeline O’Donoghue
madelineo@speedx.com.au
+61 2 8212 8512 (ext 008)

September 2017 Quarterly Operational Highlights from Rizal Resources

VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) — Rizal Resources Corporation (TSXV:RZL) (“Rizal” or the “Company”)

Rizal has continued to focus on advancing the T’Boli. Project. Development of the first production drives and preparation for stope development has continued as the mine is being prepared to significantly increase output. During the September quarter the ramp up of the T’Boli mine continued and the project continues to advance toward achieving the plant design output of 200 tonnes per day (72,000tpa).  The key immediate objective is to continue to advance the decline to open access and drive development toward material identified in the NI 43-101 Inferred resource as the South Vein.

Once the T’Boli operation is achieving sustainable steady output and generating positive cashflow, Rizal will plan and implement a drill program with the objective of extending and upgrading the resource below the existing workings.  The company also continues to implement a strategy for restructuring of its balance sheet.

Operational highlights for the September 2017 quarter

  • The production ramp-up continued during the September quarter with total gold produced (incl. gold in circuit GIC) up 69% on the June 2017 quarter at 585 oz.
  • Gold sold totalled 373 oz – an increase of 8% on the June quarter. Silver sold for the quarter totalled 832 oz which was an increase on the June quarter of 80%
  • Total gold and silver revenue totalled CAD 587,456 for the quarter, while total operating costs were CAD 884,920 delivering an operating loss CAD 297,464
  • Mill throughput for the September quarter was 9,934 t, which was 55 % of plant design output – mainly due to slower progress than planned in mine development and production.
  • Toward the end of the quarter, recoveries in the plant rose from 90% to 95%. This increase is primarily due to an increase in grade. During the quarter, grade increased from a low of 1g/t to a high at the end of the quarter of 3.52 g/t
  • The increase in grade was due to the mine progressing from remnant material to opening up and accessing virgin areas of the mine. Mining will continue to develop the lower sections of the mine below all of the old workings.
  • Water ingress issues were addressed late in the quarter through the purchase of several submersible pumps. These pumps will allow a sustainable water management program that ensures mining activities are no longer restricted.
  • The mine progressed toward our strategy of owner-operator mining as the operation moved into the production phase. Ongoing infrastructure development will be carried out by the mining contractor.
  • Mining opened up three development drives including the 525 West, South Access west and east.
  • Total metres advanced in the decline was 216m for the quarter verses a budget of 296m, while drive development totalled 40m for the period verses budget of 65m.
PRODUCTION AND SALES SUMMARY – GOLD
September 2017 Quarter
 Grams oz.  Tons Milled  Ave. grade
(grams/ton)
 Total Proceeds
 PHP  CDN($)
July 3,706.20 119.16 3,061.00 1.13 7,258,715.00 178,461.69
August 2,577.80 82.88 3,312.00 1.03 5,348,184.00 131,901.51
September 5,338.76 171.64 3,561.00 1.94 10,840,689.29 263,709.83
Total, 2017 11,622.76 373.68 9,934.00 1.39 23,447,588.29 574,073.03
PRODUCTION AND SALES SUMMARY – SILVER
September 2017
Quarter
 Grams oz.  Tons Milled  Total Proceeds
 PHP  CDN($)
July 10,231.00 328.93 3,061.00 207,004.00 5,089.37
August 5,060.00 162.68 3,312.00 106,260.00 2,620.68
September 10,601.00 340.83 3,561.00 233,222.00 5,673.34
Total, 2017 25,892.00 832.45 9,934.00 546,486.00 13,383.39

Mr Dirk Richards, BSc (Met/Chem), MAusIMM (CP Met), RPEQ, MRACI is nominated as a “Qualified Person” as such term defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43- 101”), has reviewed and verified the validity of the scientific and technical disclosure in this news release.

Peter Main
President and CEO
pmain@rizalresources.com

For   further   information  please   visit    our   website   at    www.rizalresources.com, email   us   at info@rizalresources.com
Phone: 778-370-1372 Fax: 604-608-5442

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Saudi Stock Exchange (Tadawul) Signs Post-Trade Technology Transformation Agreement with Nasdaq

Saudi Stock Exchange will transform its post-trade infrastructure 

Nasdaq to deliver new cash and derivatives clearing, central securities depository (CSD) and post-trade risk management technologies 

RIYADH, N.Y. and STOCKHOLM, Sweden, Dec. 04, 2017 (GLOBE NEWSWIRE) — The Saudi Stock Exchange (Tadawul) and Nasdaq have officially signed an agreement to transform Tadawul’s post-trade technology infrastructure, which includes registry, depository and risk management technologies. In addition to the post-trade area, Nasdaq will continue to support the existing trading and market surveillance technology at Tadawul.

The new post-trade technology, will replace Tadawul’s current registry, depository, clearing and settlement solution, which was implemented in 2001. In addition to introducing a new central counterparty clearing solution, this transformation will enable both Tadawul and market participants to introduce new asset classes to the market and offer new services to the investors. Furthermore, these changes will increase efficiency, effectiveness and further growth of the market, supported by a modern flexible and efficient technology that reduces risks in the post-trade area in compliance with international best practices and standards.

This transformation is expected to be complete during second half of 2020.

“We are very keen on investing in cutting-edge technologies to offer a fast and efficient Post Trade platform,” said Eng. Khalid Abdullah Al-Hussan, CEO, The Saudi Stock Exchange (Tadawul). “This crucial step goes hand in hand with all the market enhancements we have undertaken to integrate securities trading in Saudi Arabia with global equity markets and enhance post trade infrastructure and efficiency for local and foreign investors.”

“The ambition of Tadawul to become an innovative, world-leading exchange company is not only admirable but inspiring to our industry,” said Adena Friedman, President and CEO, Nasdaq. “By addressing the demand to overhaul, modernize and evolve its post-trade infrastructure, this demonstrates a clear vision by Tadawul to attract capital — both domestic and foreign — and present Riyadh as a major financial destination with best-in-class technology operating at its core. As a long-term partner, we are proud to be supporting Tadawul in their ambitious efforts and incredibly bright future.”

Nasdaq’s market infrastructure technologies, including trading, real-time risk, index, clearing, CSD and market surveillance systems are operated in more than 100 marketplaces, regulators, clearinghouses and central securities depositories across the Americas, Europe, Asia, Australia, Africa, the Middle East and the Caribbean.

About Tadawul
Saudi Stock Exchange (Tadawul) is the sole entity authorized in the Kingdom of Saudi Arabia to act as the kingdom’s securities exchange (the Exchange), listing and trading in securities. The Saudi stock market is the 26th largest stock market among the 67 members of the World Federation of Exchanges and is the dominant market in the Gulf Cooperation Council (GCC) comprising 48 percent of total GCC market capitalization and 73 percent of value traded.

For more information see:  www.tadawul.com.sa/wps/portal/tadawul/home/

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

NDAQG

For Media Inquiries

Nasdaq
Ryan Wells
ryan.wells@nasdaq.com
Direct: +44 (0) 20 3753 2231
Mobile:  +44 (0) 7809 596 390

Tadawul
Abdullah Alsharif
abdullah.sharif@tadawul.com.sa
Direct: +966 (11) 2189044
Mobile:  +966 (55) 5114404

UN leader calls to end fighting in Yemen

United Nations (UN) Secretary-General Antonio Guterres on Sunday expressed concern over the recent escalation of fighting in Yemen, with other UN leaders demanding the immediate resumption of commercial shipments to Yemen for the sake of the starving population.

Guterres’ spokesman Stephane Dujarric said in a statement that the secretary-general is deeply concerned about the sharp escalation of armed clashes and airstrikes in the capital city of Sanaa and other parts of Yemen over the past several days. The new conflict and the blockade imposed on Nov. 6 by the Saudi-led military coalition, which is fighting Houthi rebels, have caused significant shortages of critical supplies, especially food and fuel, and resulted in price hikes, curtailing access to food, safe water and healthcare.

The secretary-general calls on all parties to the conflict to cease all air and ground assaults.

Source: VOV5

North Korean leader hints no barrier for weapons program

Emboldened by the successful test flight of a new intercontinental ballistic missile (ICBM) last week, North Korea leader Kim Jong-un inspected a local factory that supplies goods for mobile rocket launchers, according to the Korean Central News Agency (KCNA).

During his visit to the Amnokgang Tire Factory, Kim said there’s neither a fortress that the North needs to occupy nor an impasse it needs to overcome.

Kim’s “field message” came days after the North said it has completed its nuclear force with the development of the Hwasong-15 ICBM that can reach anywhere in the United States with a super-sized nuclear warhead.

Source: VOV5